Cancer
doesn’t wait.
Neither will we.

At Bicara, we are attacking cancer head-on by combining the precision of targeted therapies with the power of tumor-microenvironment modulators to create better medicines for patients.

Who We Are

We are led by a dynamic team with extensive experience in oncology drug development and deep relationships with the world’s top cancer centers.

View Team

Our Mission

We are dedicated to improving the lives of people living with cancer through the
development of innovative targeted therapies. Our primary focus is to deliver first-in-class treatments that provide meaningful and durable benefits for patients, bringing hope and control back into their lives.

Our Lead
Program:
Ficerafusp alfa

Ficerafusp alfa (BCA101) is a first-in-class, dual-action, bifunctional EGFR/TGF-β antibody in clinical development for multiple different solid tumor cancer types, including head and neck squamous cell carcinoma, one of the most common and debilitating cancers worldwide.

View Science

Image
Background

Focused on those who matter most:
Patients & Caregivers

Our commitment to patients and their caregivers is unwavering. We believe ficerafusp alfa has the potential to improve and extend the lives of people with head and neck squamous cell carcinoma and other
cancer types.

Learn More

~0K

New HNSCC cases per year globally

~0K

Deaths from HNSCC per year

page callout image

Join Us On Our Mission

Bicara is a dynamic company looking for talented individuals to join our team. Our employees have a shared passion to advance meaningful new therapies for people living with cancer.

Explore Careers